Apomorphine intranasal - Britannia

Drug Profile

Apomorphine intranasal - Britannia

Latest Information Update: 09 Jun 2010

Price : $50

At a glance

  • Originator Britannia Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Erectile dysfunction; Parkinson's disease

Most Recent Events

  • 30 May 2007 Apomorphine-intranasal is available for licensing for male erectile dysfunction worldwide (http://www.britannia-pharm.co.uk/partnerships.shtml)
  • 30 May 2007 Apomorphine-intranasal is available for licensing for PD worldwide, excluding the UK and North America (http://www.britannia-pharm.co.uk/partnerships.shtml)
  • 23 Jan 2004 Clinical data from a media release have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top